Photo: Jellybee

Is Ginger good for prostate health?

The present study reports a novel finding that oral consumption of the extract of whole ginger, a commonly consumed vegetable worldwide, significantly inhibits prostate tumour progression in both in vitro and in vivo mice models.

cambridge.org - Benefits of whole ginger extract in prostate cancer

How much dark chocolate is anti-inflammatory?

In a small study from 2018 , researchers found that eating 30 g of 84% dark chocolate each day for 8 weeks significantly reduced inflammatory...

Last updated May 15, 2020

What are the symptoms of stickler syndrome?

Also known as hereditary progressive arthro-ophthalmopathy, Stickler syndrome is usually diagnosed during infancy or childhood. Children who have...

Last updated Aug 10, 2018

Promotion

Prostate cancer is the most common non-cutaneous malignancy in American men, afflicting one in six men. It is estimated that in the USA, one new case occurs every 2·4 min and a death results every 16·4 min from prostate cancer. Clinically significant prostate cancer appears to develop over 20–30 years, thus presenting a ‘large window’ of opportunity for interventional chemopreventive strategies(Reference Syed, Khan and Afaq1, Reference Nelson, De Marzo and Isaacs2). Although the traditional focus has been on treating existing tumours with chemotherapeutic agents that most often exert toxic side effects, development of chemopreventive approaches that can prevent, suppress or reverse progression to invasive cancer represents a relatively young field with tremendous promise to reduce cancer burden(Reference Sporn3, Reference Mann, Backlund and DuBois4). Laboratory and epidemiological research during the past three decades has provided indisputable evidence, indicating that high intake of fruits and vegetables is linked to a reduced cancer susceptibility including prostate cancer risk(Reference Kaur, Agarwal and Agarwal5–Reference Yang, Landau and Huang7). Several National Cancer Institute (NCI) initiatives continue to underscore the importance of including fruits and vegetables in the daily diet as a cancer chemopreventive measure(Reference Kaur, Agarwal and Agarwal5, Reference Traka, Gasper and Melchini8–Reference Colli and Amling10). Fruits and vegetables contain phytochemicals (carotenoids, polyphenolics, anthocyanins, alkaloids, N and S compounds) that have been shown to target multiple neoplastic stages to reduce overall cancer risk(Reference Craig11). About thirty-five plant-based foods identified by the NCI to be effective in cancer prevention include garlic, ginger, turmeric, cruciferous vegetables (broccoli, brussel sprouts, cabbage) and grape seed extracts(Reference Surh12). Ginger (Zingiber officinale Roscoe), a rhizomatous perennial plant used worldwide as a spice in foods and beverages, is commonly known for its medicinal properties, primarily as a remedy for digestive disorders, including dyspepsia, colic, nausea, vomiting, gastritis and diarrhoea(Reference Zick, Djuric and Ruffin13). Ginger is known to contain several bioactive phenolic compounds, including non-volatile pungent compounds such as gingerols, paradols, shogaols and gingerones(Reference Shukla and Singh14). The most abundant phytochemicals, gingerols, vary in chain length and comprise odiferous components of the fresh root, with 6-gingerol being the most imperative one(Reference Zick, Djuric and Ruffin13). The dehydrated form of gingerols, shogaols, mainly occurs in the dried roots, with 6-shogaol being the most abundant one(Reference Zick, Djuric and Ruffin13). The constituent phenolics of ginger have been shown to display antioxidant(Reference Shobana and Naidu15), anticancer(Reference Katiyar, Agarwal and Mukhtar16), anti-inflammatory(Reference Surh17), anti-angiogenesis(Reference Kim, Min and Kim18, Reference Kim, Kundu and Shin19) and anti-artherosclerotic(Reference Fuhrman, Rosenblat and Hayek20) properties. Although the constituent phytochemicals present in ginger, in particular, gingerols, shogaols and paradols, are being rigorously tested for their anticancer properties, it is becoming increasingly recognisable that the gainful effects of fruits and vegetables are due to an additive and/or synergistic interplay of the composite mixture of phytochemicals present in whole foods rather than the constituent single agents alone(Reference Liu21). In the context of ginger root, sufficient evidence suggests that achievable plasma concentrations of individual phytochemicals are in a very low micromolar range (2 μg/ml or less)(Reference Zick, Djuric and Ruffin13). In addition, these phytochemicals are found primarily in the form of their non-active glucuronide or sulphate metabolites, and therefore the anticancer effects observed with much higher concentrations in vitro may not be relevant in the in vivo milieu(Reference Yang22, Reference Jankun, Selman and Swiercz23). Thus, sufficient accumulating evidence suggests that the repertoire of phytochemicals present in dietary agents works together through complementary and overlapping mechanisms to present optimal cancer chemopreventive and therapeutic benefits(Reference Liu24). With this mindset, we sought to undertake a detailed evaluation of the in vitro and in vivo anticancer activity of whole ginger extract (GE) in prostate cancer. To the best of our knowledge, there is not even a single report that presents a thorough mechanistic investigation to develop GE for prostate cancer management. Herein, we examined the in vitro and in vivo anticancer effects of GE in prostate cancer by evaluating its effects on cellular proliferation, cell-cycle progression and apoptosis. We found that GE resulted in growth inhibition, cell-cycle arrest and induced caspase-dependent intrinsic apoptosis in prostate cancer cells. In vivo studies suggested that GE significantly inhibited tumour growth in human PC-3 xenografts implanted in nude mice without any detectable toxicity. All the experiments were repeated at least three times. Results are expressed as mean values of at least three independent experiments and standard deviations, and P values (Student's t test) were calculated in reference to control values using Excel software. After 8 weeks of vehicle or 100 mg/kg GE treatment, tumour, lung, spleen, adrenal, liver, gut, brain, kidney, heart, testes and bone marrow were formalin-fixed, paraffin-embedded and 5 μm thick sections were stained with Ki67, cleaved caspase-3, PARP and haematoxylin and eosin. Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL) staining of tumour tissue sections was performed using the DeadEnd Fluorometric TUNEL System (Promega Inc., Madison, WI, USA) according to the manufacturer's instructions. Male Balb/c nude mice (6 weeks old) were obtained from the NCI (Frederick, MD, USA), and 10 6 PC-3 cells in 100 μl PBS were injected subcutaneously in the right flank without any basement membrane extracts such as Matrigel. The animals were given autoclave-sterilised standard diet pellets and water ad libitum. When tumours were palpable, mice were randomly divided into two groups. From each group, six mice were housed individually in one cage. The control group received vehicle and the treatment group received 100 mg/kg body weight of GE daily by oral administration. Tumour growth was monitored weekly using a vernier caliper and body weight was also recorded. All animal experiments were performed in compliance with the Institutional Animal Care and Use Committee (IACUC) guidelines. Control or 250 μg/ml of GE-treated lysates were tested for caspase-3-like activity using Ac-DEVD-7-amino-4-trifluoromethyl-coumarin, which detects the activities of caspase-3 and caspase-7 according to the manufacturer's protocol (Calbiochem, San Diego, CA, USA). The results were evaluated using a fluorescence microplate reader and are expressed as relative fluorescence units. After treatment with 250 μg/ml of GE, PC-3 cells taken on glass coverslips were fixed with ice-cold methanol, followed by blocking with 2 % bovine serum albumin in PBS. Ki67, cleaved caspase-3 and PARP antibodies (1:250 dilution) were incubated with coverslips for 2 h at 37°C. The cells were washed with 2 % bovine serum albumin/PBS for 10 min at room temperature before incubating with a 1:500 dilution of Alexa 488- or Alexa 555-conjugated secondary antibodies. Cells were mounted with Prolong Gold antifade reagent that contains 4,6-diamidino-2-phenylindole (Invitrogen, Carlsbad, CA, USA). To determine the release of cytochrome c from the mitochondria to the cytosol by immunoblotting, control or GE-treated (250 μg/ml) PC-3 cells were incubated on ice for 5 min in 100 μl of ice-cold cell lysis and mitochondria intact buffer (250 mm-sucrose, 70 mm-KCl and 100 μg digitonin/ml in PBS). The cells were pelleted and the supernatant containing cytosolic protein was stored at − 80°C. The pellets were incubated at 4°C for 10 min in immunoprecipitation buffer (50 mm-Tris-HCl (pH 7·4), 150 mm-NaCl, 2 mm-EDTA, 2 mm-ethylene glycol tetra-acetic acid, 0·2 % Triton X-100, 0·3 % Nonidet P-40, 1 × Complete protease inhibitor; Roche Diagnostics Corporation, Indianapolis, IN, USA). The samples were centrifuged at high speed for 10 min at 4°C, and the supernatant containing mitochondrial protein was stored at − 80°C ( Reference Waterhouse, Goldstein and von Ahsen 27 ) . Proteins were subjected to immunoblot analysis as described above. Western blots were performed as described earlier ( Reference Karna, Zughaier and Pannu 26 ) . Briefly, proteins were resolved by polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked in Tris-buffered saline containing 0·05 % Tween-20 and 5 % fat-free dry milk and incubated first with primary antibodies and then with horseradish peroxidase-conjugated secondary antibodies. Specific proteins were visualised with enhanced chemiluminescence detection reagent according to the manufacturer's instructions (Pierce Biotechnology, Rockford, IL, USA). For cell-cycle analysis, PC-3 cells were treated with vehicle (dimethyl sulfoxide) or GE at various doses (50, 100, 250, 500 and 1000 μg/ml) for 24 h or at a fixed dose of 250 μg/ml for various time points (12, 24, 48 and 72 h). At the end of incubation, cells were fixed with 70 % ethanol overnight, stained with propidium iodide containing RNase A, followed by data acquisition on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and analyses using Flo-Jo software (Ashland, OR, USA). Cells were plated in ninety-six-well plates and treated with gradient concentrations (1–1000 μg/ml) of GE the next day. After 72 h of incubation, cell proliferation was determined using the Alamar blue cell proliferation assay. The magnitude of the fluorescent signal is proportional to the number of live cells, and is monitored using 530–560 nm excitation wavelength and 590 nm emission ( Reference Nociari, Shalev and Benias 25 ) wavelength. For the colony assay, PC-3 cells were treated with 250 μg/ml of GE for 48 h, washed and replaced with regular RPMI medium. After 10 d, colonies were fixed with 4 % formaldehyde, stained with crystal violet and counted. Normal prostate epithelial cells (PrEC) and prostate cancer (LNCaP, C4-2, C4-2B, DU145 and PC-3), breast (MDA-MB-231 and MCF-7) and cervical (HeLa) cancer cell lines were used in the present study. The medium used to culture these cells was Roswell Park Memorial Institute-1640 (RPMI-1640) or Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum and 1 % antibiotic (penicillin/streptomycin). Primary antibodies to p21, cyclin E and BAX and horseradish peroxidase-conjugated secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cyclin D1, cdk4, p-Rb, Bcl2, cytochrome c, cleaved caspase-3 and cleaved poly(ADP-ribose)polymerase (PARP) were from Cell Signaling (Beverly, MA, USA), Ki67 was from Zymed (South San Francisco, CA, USA) and β-actin was from Sigma (St Louis, MO, USA). Ginger was obtained from the local farmer's market and extracts were prepared by soaking grated ginger in methanol overnight for four consecutive days. The supernatant was collected daily and was finally concentrated in vacuo (Buchi Rotavap, Buchi, Switzerland), followed by freeze-drying using a lyophiliser to a solid powder form. GE stock solution was prepared by dissolving 100 mg/ml of dimethyl sulfoxide, and various concentrations were obtained by appropriate dilutions. The entire study was conducted using a single batch of GE to avoid batch-to-batch variation and maximise the product constancy.

What foods burn belly fat at night?

Best Foods to Eat Before Bed for Weight Loss Whey Protein Shake. First and foremost, protein is important for weight loss - whey protein included!...

Last updated Sep 2, 2020

Is peanut high in uric acid?

Animal proteins generally contain the largest amounts of purines. If you have gout, you might need to restrict your intake of high-purine foods....

Last updated May 23, 2022

Promotion

Results

Ginger extract displays selective antiproliferative activity in prostate cancer cells Although the whole GE has been shown to inhibit proliferation of breast(Reference Lee, Seo and Kang28) and colon cancer cells(Reference Jeong, Bode and Pugliese29), there are no available reports that have tested the potential usefulness of GE in prostate cancer. Thus, we first asked whether GE affected the proliferation of prostate cancer cells. To this end, we investigated the effect of GE on PC-3, LNCaP, C4-2, C4-2B and DU145 cells, which are well-characterised representatives of androgen-responsive (LNCaP) and androgen-independent (PC-3, C4-2 and C4-2B) human prostate cancers. Cells were treated with increasing gradient concentrations of GE or vehicle (0·1 % dimethyl sulfoxide) for 72 h, and cell survival was assessed by the Alamar blue assay. Our data showed that GE inhibited cellular proliferation of all prostate cancer cells, with a half-maximal concentration of growth inhibition (IC 50 ) in the order C4-2 (512 μg/ml)>PC-3 (250 μg/ml)>C42-B (240 μg/ml)>DU145 (95 μg/ml)>LNCaP (75 μg/ml) (Fig. 1(A) and 1(B)). These data suggested the generality of the growth inhibition effect of GE on prostate cell lines with varying genotypic backgrounds. Hereupon, we focused on PC-3 cells for further experimentation to delineate molecular mechanisms of growth inhibition and cell death. We also performed a complementary trypan blue assay to examine cell viability on GE treatment in a concentration- and time-dependent manner in PC-3 cells (see Fig. S1 of the supplementary material, available online at http://www.journals.cambridge.org/bjn). Yet another screen of an array of cancer cell lines from different tissue types, namely breast and cervical cancer, showed that GE affected the proliferative capacity of these cancer cells (see Fig. S2 of the supplementary material, available online at http://www.journals.cambridge.org/bjn), suggesting generalisation of GE effects on cell lines from other tissue types. Tumour cell selectivity is a highly desirable trait of any chemopreventive or chemotherapeutic regimen. To investigate whether GE-mediated suppression of PC-3 cell growth was selective to cancer cells, we determined the effect of GE treatment on a normal PrEC and serum-starved human dermal primary fibroblast (HDF) cells. Our choice of cell lines was based on the fact that PrEC and HDF exhibit features most consistent with the epithelial cells of prostate and dermal origin, respectively. The present results showed that the viability of PrEC or HDF was not significantly affected by GE treatment at concentrations in the range of 100–750 μg/ml (Fig. 1(B)). The IC 50 of PrEC (1750 μg/ml) and HDF (1000 μg/ml) was approximately 6·9- and approximately 4-fold higher, respectively, compared with PC-3 cells, reflecting the wide therapeutic window that imparts tumour selectivity. Collectively, these results indicated that PC-3 cells, but not normal prostate epithelial or primary fibroblast cells, were significantly sensitive to growth inhibition by GE treatment. Next, we performed a clonogenic cell survival assay to determine the ability of cells to proliferate indefinitely upon drug removal, thereby measuring their reproductive capacity to form colonies. Our data showed that 250 μg/ml of GE decreased colony numbers by approximately 66 % (Fig. 1(C)) compared with vehicle-treated controls. Representative pictures of surviving crystal violet-stained PC-3 cell colonies from control and GE-treated cells are shown in Fig. 1(C). Several model systems have shown that Ki67 expression shows a good direct relationship with growth fraction, and thus serves as a reliable method for evaluating actively proliferating cell populations. Immunostaining with an antibody that reacts with the Ki67 nuclear antigen showed significantly intense staining in control cells compared with 250 μg/ml of GE-treated cells (Fig. 1(Di)). Fig. 1(Diii) is a bar graph representation of Ki67-positive cells scored as an average in both control and GE-treated samples from at least ten fields of vision totalling 200 cells. These data correlated with our previous in vitro proliferation and colony survival data, thus confirming the antiproliferative activity of GE. Several characteristics of apoptosis, such as morphological and cellular changes, including chromatin condensation, membrane blebbing and DNA fragmentation, lend themselves to assessment. Thus, we microscopically examined DAPI-stained control and 48 h GE-treated (250 μg/ml) cells to observe condensed chromatin material and other morphological features reminiscent of apoptosis. Representative fluorescence micrographs are shown in Fig. 1(Dii) and their bar graph quantification is depicted in Fig. 1(Diii). Ginger extract arrests cell-cycle progression at the G1 and S phase, followed by emergence of sub-G1 population Several dietary agents have been shown to arrest the cell cycle, leading to growth inhibition and apoptosis. For example, grape seed proanthocyanidins, green tea polyphenols, epigallocatechin-3-gallate, resveratrol (red grapes, peanuts and berries), silymarin/silibinin (milk thistle), genistein (soyabean), curcumin (turmeric) and ginger (gingerols) affect cell-cycle progression at various stages by specifically modulating cell-cycle-associated proteins(Reference Aggarwal and Shishodia30, Reference Meeran and Katiyar31). Specific gingerols, such as 6-gingerol and 8-gingerol, have been shown to perturb cell-cycle progression as a chemopreventive strategy(Reference Park, Wen and Bang32). Thus, our next aim was to gain mechanistic insights into GE-mediated antiproliferative activity by determining the specific cell-cycle stage at which GE intervenes. To this end, we examined the cell-cycle distribution profile of GE-treated PC-3 cells by employing a flow cytometric assay using the DNA intercalator dye, propidium iodide. Fig. 2(A) shows the effect of varying GE dose levels on cell-cycle progression of PC-3 cells at 24 h of treatment in a three-dimensional disposition. As shown in Fig. S3(A) of the supplementary material (available online at http://www.journals.cambridge.org/bjn), exposure of PC-3 cultures consistently resulted in a statistically significant dose-dependent enrichment of the sub-G1 fraction, suggesting considerable apoptotic cell death. The sub-G1 population increased from approximately 6 % at 100 μg/ml to approximately 99 % at 1000 μg/ml. Fig. S3(A) of the supplementary material (available online at http://www.journals.cambridge.org/bjn) bar-graphically depicts the percentages of G1, S, G2/M and sub-G1 phase populations in PC-3 cells upon treatment with varying GE doses (0–1000 μg/ml). Next, we used the half-maximal sub-G1 dose (250 μg/ml) to explore in depth the effect of GE on each cell-cycle phase at the time of treatment (Fig. 2(B)). The present results showed that GE at a dose level of 250 μg/ml caused accumulation of cells in the G1 and S phase at as early as 6- and 12 h of GE treatment, respectively. The cell-cycle arrest was followed by an emergence of a hypodiploid sub-G1 population, a hallmark of dying apoptotic cells. The cell-cycle kinetics, as evident by the percentage of cells in various cell-cycle phases over time, is depicted in the form of a bar graph in Fig. S3(B) of the supplementary material (available online at http://www.journals.cambridge.org/bjn). The sub-G1 population began to appear at as early as 6 h and peaked at 48 h (approximately 67 %). To further understand the interrelationships between the effect of GE on cell-cycle arrest and induction of apoptosis, we devised timed exposure experiments using two regimens. The first regimen involved low GE concentration (50 μg/ml) for a longer time (72 h), whereas the second regimen was exposure to a higher GE dose (1000 μg/ml) for a shorter duration (6 h). Essentially, the idea was to delineate whether either treatment regimen caused cell-cycle arrest and/or apoptosis simultaneously or sequentially. The present results indicated that short-term exposure of higher concentration induced considerable cell death (approximately 35 %) without any apparent cell-cycle arrest, whereas long-term exposure to a lower dose induced cell-cycle arrest (G2/M) and significant cell death or apoptosis (approximately 50 %; see Fig. S4 of the supplementary material, available online at http://www.journals.cambridge.org/bjn). This suggested that long-term exposure (72 h) to low-dose (50 μg/ml) GE induced cell-cycle arrest, which perhaps lends sufficient time for enhanced expression of pro-apoptotic molecules that ultimately results in a higher proportion of sub-G1 cells (50 %), indicative of apoptosis. Taken together, these observations imply that the growth inhibition of PC-3 cells by GE results from a combination of apoptosis and cell-cycle derangements, in which cell-cycle arrest may be a key event. The simultaneous appearance of cell-cycle arrest and apoptosis at a low dose for a longer time perhaps suggests that cell death may be ascribed to the activation of apoptotic pathways as a consequence of the inability of the cells to overcome growth arrest and proceed through the cell cycle. Nonetheless, on the basis of the appearance of sub-G1 cells at 6 h after treatment with 1000 μg/ml of GE, we cannot exclude the possibility that cell death may be a primary direct effect of GE. It is also likely that other non-apoptotic means of cell death at either treatment regimen might exist. However, the end result of both perturbations (low-dose, long-term and high-dose, short-term) is induction of PC-3 cell death. These data suggest that GE could potentially be tested as a potential chemopreventive as well as a chemotherapeutic agent for prostate cancer management. Effect of ginger extract treatment on cell-cycle and apoptosis regulatory molecules We next sought to determine molecular mechanisms underlying GE-induced cell-cycle stasis and subsequent apoptosis. Essentially, cell-cycle progression involves sequential activation of cdks by their cyclical association with cell-cycle phase-specific regulatory cyclin molecules(Reference Grana and Reddy33). To examine GE-induced alterations, we first determined the effect of 250 μg/ml of GE on protein levels of G1/S-specific cyclins and cdks by immunoblotting methods. GE treatment caused a marked decrease in cyclin D1 levels in PC-3 cells, which was evident as early as 12 h post-treatment (Fig. 2(C)). In addition, GE-treated PC-3 cells exhibited a slight decrease in cdk4 levels (Fig. 2(C)). Our data also showed that GE caused a significant reduction in cyclin E levels, which drive the cell cycle primarily through the S phase in association with cdk2. Elevated levels of p21, a cdk inhibitor, function to stall the cell cycle(Reference Besson, Dowdy and Roberts34). Essentially, p21 plays a crucial role in the regulation of the G1/S and G2/M transition by binding to and inhibiting the kinase activity of cyclin/cdk complexes. To explore further, we determined the effect of GE treatment on protein expression and/or phosphorylation of p21 and Rb by immunoblotting methods. As shown in Fig. 2(C), GE treatment caused an induction of p21 protein expression in PC-3 cells, which was evident at 12–24 h. In addition, GE treatment caused suppression of Rb phosphorylation in PC-3 cells (Fig. 2(C)). Effect of ginger extract treatment on Bcl-2 family members Multiple apoptotic pathways are recruited by cells for executing their own demise via apoptosis. Among them, one major mechanism involves the loss of mitochondrial membrane integrity and transmembrane potential (Ψm)(Reference Green and Reed35). We thus asked whether GE affected mitochondrial transmembrane potential. To this end, we stained GE-treated cells with JC-1, a cationic dye that displays potential-dependent accumulation in the mitochondria. A decrease in the red:green fluorescence intensity ratio suggested mitochondrial depolarisation (Fig. 2(Di)). The increase in the green JC-1 monomeric form, indicative of collapse of transmembrane potential, was quantitatively determined using flow cytometry. Quantification of fluorescence-activated cell sorting data indicated an approximately 3·6-fold increase (Fig. 2(Dii)) in the mean fluorescence intensity of GE-treated JC-1-stained cells compared with controls (Fig. 2(Dii)). A spectral shift and loss of red fluorescence, which is consistent with decreased polarisation, was also observed (Fig. 2(Ei) and (Eii)). The collapse of Ψm is closely associated with alterations in the ratio of anti-apoptotic:pro-apoptotic members of the Bcl2 family, which determines susceptibility to apoptosis(Reference Adams and Cory36). Particularly, loss of Ψm is coupled with hyperphosphorylation and thus inactivation of the anti-apoptotic molecule Bcl2, which promotes recruitment of BAX onto the outer mitochondrial membrane. BAX incorporation results in uncoupling of the respiratory chain and efflux of small pro-apoptotic factors, such as cytochrome c, leading to the activation of key executioner caspases, caspase-3/7. Thus, our next step was to investigate the effect of GE treatment on levels of Bcl-2 family proteins by immunoblotting and the results are shown in Fig. 3(A). GE treatment caused a rapid and marked increase in BAX expression over time, whereas levels of total Bcl2 were decreased (Fig. 3(A)). The GE-mediated alterations in the pro-apoptotic/anti-apoptotic molecules were evident as early as 12 h post-treatment and increased thereafter (Fig. 3(A)). Biochemical events, such as the release of cytochrome c from the mitochondria into the cytosol, caspase activation and PARP cleavage, predominantly occur during mitochondria-mediated apoptotic cell death. Thus, we asked whether GE-induced cell death promoted the release of apoptogenic factors from the mitochondria that triggered the downstream executioner events of apoptosis. Our data showed that cytochrome c was detectable at 12 h and peaked at 48 h of GE treatment in the cytosolic fraction, as observed using immunoblotting methods (Fig. 3(A)). Immunofluorescence microscopic methods also showed translocation of cytochrome c into the cytosol at 24 h of GE treatment (see Fig. S5 of the supplementary material, available online at http://www.journals.cambridge.org/bjn).

What cancers can be detected in urine?

Urine cytology is used with other tests and procedures to diagnose cancers of the urinary tract, including: Bladder cancer. Cancer of the ureter....

Last updated Nov 14, 2022

What food cleans your heart arteries?

Here are some of the best foods that unclog arteries to eat in order to prevent or clean clogged arteries. Berries. Strawberries, blueberries,...

Last updated Mar 11, 2021

Promotion

Activation of executioner caspase-3 and cleavage of poly(ADP-ribose)polymerase Our next aim was to explore the involvement of caspases that are activated by the release of cytochrome c and are known to cleave a variety of substrates. Since caspase-3 activation is considered as a hallmark of apoptosis, we monitored the active form of the cysteine protease using a small, conserved, modified peptide substrate that becomes fluorogenic upon cleavage. As shown in Fig. 3(B), GE stimulated a time-dependent increase of caspase-3 activity in PC-3 cells. However, treatment of cells with a specific inhibitor of caspase-3 significantly blocked GE-induced apoptotic cell death (data not shown). Furthermore, immunoblots showed a time-dependent increase in expression levels of activated caspase-3, suggesting that GE-induced cell death is caspase-3 dependent (Fig. 3(A)). On caspase-3 activation, a number of cellular proteins are cleaved, including PARP. The present results showed a time-dependent increase in cleaved PARP levels, a substrate of caspase-3. An increase in the expression of both activated caspase-3 and cleaved PARP was also confirmed in GE-treated cells by immunofluorescence microscopic methods (Fig. 3(Ci) and (Di)). Quantification was performed by scoring positive cells in control and GE-treated PC-3 cells from several random image fields totalling 200 cells (Fig. 3(Cii) and (Dii)). We also examined the ability of GE to induce apoptosis in androgen-responsive LNCaP cells, and our data showed a dose-dependent increase in the sub-G1 population evaluated at 24 h of GE treatment (Fig. S6(A)). There was also an increase in cleaved caspase-3 levels and caspase-3 activity, as shown in Fig. S6(B) and (C) of the supplementary material (available online at http://www.journals.cambridge.org/bjn). Oral ginger extract feeding achieves inhibition of PC-3 tumours in nude mice Having identified significant antiproliferative and pro-apoptotic activity of GE, an intriguing question was to determine whether the anticancer effects of GE were restricted to in vitro cultures or extended to in vivo systems. To validate this, we examined the efficacy of GE to inhibit human prostate PC-3 xenografts subcutaneously implanted in athymic nude mice. Animals in the treatment group were fed daily with 100 mg/kg GE. The GE was dissolved in PBS containing 0·5 % Tween-80 and was fed by oral administration for 8 weeks; responses to GE treatment were followed by tumour volume measurements every consecutive day using vernier calipers (Fig. 4(A)). Tumours in vehicle-treated control animals showed unrestricted progression (Fig. 4(A)), whereas GE feeding showed a time-dependent inhibition of tumour growth over 8 weeks (Fig. 4(A)). A reduction in tumour burden by approximately 56 % was observable after 8 weeks of 100 mg/kg per d oral feeding, and the difference between the mean final tumour volumes in animals receiving GE and those receiving vehicle orally was statistically significant (P < 0·05). All animals in the control group were euthanised by day 60 post-inoculation, in compliance with the IACUC guidelines. To assess the overall general health and well-being of animals during GE treatment, body weights were recorded twice a week. GE-treatment was well tolerated, and mice maintained normal weight gain (Fig. 4(B)) and showed no signs of discomfort during the treatment regimen. At the end point of the animal experiments (week 8), the excised tumours were weighed and an approximately 53 % reduction in tumour weight was observed in the GE-treated group compared with controls (see Fig. S7 of the supplementary material, available online at http://www.journals.cambridge.org/bjn). In vivo mechanisms of ginger extract-mediated inhibition of tumour growth To investigate the in vivo mechanisms of tumour inhibition, we first examined haematoxylin- and eosin-stained tumour sections from control and GE-treated mice. Tumour microsections from GE-treated mice showed large areas of tumour cell death, seen as tumour necrosis adjacent to normal-looking healthy cells. Significant loss of tumorigenic cells in GE-treated animals (Fig. 4(C)) was consistent with the therapeutic effect of GE. However, some viable tumour cells were observed at the periphery of cell death zones. In contrast, microsections from control tumour tissues revealed sheets of tumour cells with high-grade pleomorphic nuclei (Fig. 4(C)). We next evaluated the in vivo effect of GE feeding on the antiproliferative response associated with the inhibition of tumour growth. To this end, tumour tissue lysates were analysed for cyclins (D1, E and B1) and a cyclin-dependent kinase inhibitor, p21, using immunoblotting methods (Fig. 4(D)). GE treatment caused a decrease in cyclin D1, cyclin E and cyclin B1, whereas it increased p21 expression levels, which allied with the present in vitro findings in PC-3 cells (Fig. 2(C)). Alterations of these cell-cycle regulatory molecules in tumour tissue from GE-treated mice suggest a potential mechanism for inhibition of tumour proliferation, in keeping with the inhibition of cell-cycle kinetics observed in vitro (Fig. 2(A) and (B) and see Fig. S3(A) and (B) of the supplementary material, available online at http://www.journals.cambridge.org/bjn). In vivo apoptotic responses of GE feeding in mice bearing PC-3 tumour xenografts were evaluated by immunoblotting of tumour lysates for cleaved caspase-3 expression. We further correlated the in vivo molecular mechanisms of GE treatment by immunostaining for Ki67, a marker for cell proliferation, as well as apoptotic markers such as cleaved caspase-3, cleaved PARP and TUNEL (Fig. 5(A)). Tumour samples from the treated groups receiving GE showed marked reduction in Ki67-positive cells compared with controls (Fig. 5(A)). There was a significantly higher expression of cleaved caspase-3 (approximately 12-fold) and PARP (approximately 35-fold) in tumour-tissue from the GE-treated groups compared with controls (Fig. 5(A) and (B)). We found an approximately 18-fold increase in TUNEL-positive cells in GE-treated tumours compared with controls (Fig. 5(A) and (B)). Fig. 5(B) shows bar graph quantitative representation of the immunostaining data from the control and GE-treated groups.

cambridge.org - Benefits of whole ginger extract in prostate cancer

What brings down PSA?

Tips for Naturally Lowering PSA Levels If you've had your prostate-specific antigen (PSA) tested and your numbers were higher, you and your doctor...

Last updated Jan 1, 2020

Is Morning sperm better?

Myth 4: Is it better to have sex at a certain time of day? Studies show that sperm count is slightly higher in the morning. This may make morning...

Last updated Jan 20, 2020

Promotion

How is health status measured?

The health status of a population can be measured by a wide range of factors: birth and death rates, life expectancy, quality of life, morbidity...

Last updated Jun 19, 2018

Promotion

What naturally makes your hair thicker?

Proper nutrition. A nutritious diet that contains healthy fats, protein, and a range of vitamins can help thicken thinning or thin hair. In fact,...

Last updated Feb 23, 2020